Skip to main content
TipRanks
Go Ultimate75% OFF

enGene Holdings (ENGN) Stock Price & Analysis

300 Followers

ENGN Stock Chart & Stats

$1.85$0.13(7.56%)
At close: 4:00 PM EST
$1.5$1.75$2$2.25Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.65 - $1.95
52-Week Range
$1.40 - $12.25
Previous Close
$1.72
Volume
N/A
Average Volume (3M)
1.53M
Market Cap
$115.27M
Enterprise Value
-$108.30M
Total Cash (Recent Filing)
$266.32M
Total Debt (Recent Filing)
$33.27M
Price to Earnings (P/E)
―
Beta
0.64
Next Earnings
Dec 23, 2026 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress

FDA alignment on key elements of a planned BLA can reduce regulatory uncertainty and give the lead program a clearer development path. Combined with reported pivotal Cohort 1 results, this supports continued clinical execution and may improve the company’s ability to advance detalimogene toward commercialization.

Balance Sheet Strength

Very low leverage gives enGene greater financial flexibility than a highly indebted clinical-stage company. The relatively small debt burden can reduce financing pressure and preserve strategic options while management funds clinical development, despite the company remaining dependent on its cash resources.

Narrower Net Loss

The substantial reduction in reported net loss indicates improved loss performance relative to 2025 and could support more disciplined capital deployment. Although enGene remains unprofitable and has no revenue base, a narrowing loss profile is a constructive operating trend if it persists during continued clinical investment.

Bears Say

No Product Revenue

The absence of reported revenue means enGene has not yet demonstrated a commercial income stream to support its operations. Its financial outlook therefore remains tied to successful clinical development, regulatory approval, and eventual launch of drug candidates rather than an established recurring business.

Persistent Cash Burn

Sustained negative operating and free cash flow requires enGene to use existing liquidity or obtain additional funding to continue operations and clinical programs. Continued cash outflows can reduce financial flexibility over time, even with a relatively strong balance sheet and low current leverage.

Unproven Commercial Model

Because enGene is still clinical-stage, its potential revenue model has not yet been validated through product sales or confirmed recurring partnerships. The business must convert development programs into approved products or licensing transactions, creating material execution dependence over the next several quarters.

enGene Holdings News

ENGN FAQ

What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $1.40 and its highest was $12.25 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $115.27M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s next earnings report is estimated for Dec 23, 2026 (not yet confirmed), which is in 34 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Sep 08, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.427 by -$0.043.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a quarterly dividend of $0.13 which represents an annual dividend yield of ―. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.47.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 67,016,320 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.427. Following the earnings report the stock price went up 5.495%.
Which hedge fund is a major shareholder of enGene Holdings?
Hedge funds hold enGene Holdings shares: the largest hedge-fund position in enGene Holdings is 72,412,774 shares, and hedge funds decreased their holdings by 1.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology